Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update

Arch Med Sci Atheroscler Dis. 2023 Feb 23:8:e1-e10. doi: 10.5114/amsad/160950. eCollection 2023.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.

Keywords: coronavirus disease 2019; liver injury; nonalcoholic fatty liver disease; severe acute respiratory syndrome coronavirus 2.